Tanvi Varadkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tanvi Varadkar has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Lufang Zhou
The Ohio State University 2 Department of Biomedical Engineering Columbus, Ohio
21 shared publications - Xiaoguang Margaret Liu
The Ohio State University 1 Department of Chemical and Biomolecular Engineering Columbus, Ohio
21 shared publications - Davis Ballard
The Ohio State University 1 Department of Chemical and Biomolecular Engineering Columbus, Ohio
17 shared publications - Jiashuai Zhang
The Ohio State University 2 Department of Biomedical Engineering Columbus, Ohio
17 shared publications - Natsorn Watcharadulyarat
The Ohio State University 1 Department of Chemical and Biomolecular Engineering Columbus, Ohio
17 shared publications - Phoebe Hu
The Ohio State University 1 Department of Chemical and Biomolecular Engineering Columbus, Ohio
17 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Characterization of CD276 expression and evaluation of humanized CD276 mAb binding and cross-species specificity. A, TCGA mRNA and protein analysis of CD276 expression in normal breast and breast cancers. **, P < 0.01; ***, P < 0.001. B, Representative image showing high CD276 expression in human TNBC tissue. Scale bar equals 70 μm. C, Representative IHC images of human normal organs stained with our humanized CD276 mAb. Scale bar equals 70 μm. D, Representative IHC images of monkey, mouse, and rat normal organs stained with humanized CD276 mAb. Scale bar equals 70 μm. E, Binding affinity (KD values) of humanized CD276 mAb for CD276 receptors from human, monkey, mouse, and rat. F, Flow cytometry analysis of humanized CD276 mAb binding to the surface of human and mouse TNBC cells and rat breast cancer cells. SSC, side scatter.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Characterization of CD276 expression and evaluation of humanized CD276 mAb binding and cross-species specificity. A, TCGA mRNA and protein analysis of CD276 expression in normal breast and breast cancers. **, P < 0.01; ***, P < 0.001. B, Representative image showing high CD276 expression in human TNBC tissue. Scale bar equals 70 μm. C, Representative IHC images of human normal organs stained with our humanized CD276 mAb. Scale bar equals 70 μm. D, Representative IHC images of monkey, mouse, and rat normal organs stained with humanized CD276 mAb. Scale bar equals 70 μm. E, Binding affinity (KD values) of humanized CD276 mAb for CD276 receptors from human, monkey, mouse, and rat. F, Flow cytometry analysis of humanized CD276 mAb binding to the surface of human and mouse TNBC cells and rat breast cancer cells. SSC, side scatter.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S2 shows single ADCs structure and HPLC characterization.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S2 shows single ADCs structure and HPLC characterization.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 6 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
In vivo anti-TNBC efficacy of DualADCs in 4T1-Fluc xenograft immunocompetent mouse models. ADCs or saline (16 mg/kg) were i.v. injected via the tail vein. A, Tumor volume measurement with black arrows indicating treatments or saline (n = 4). B, Body weight. C, H&E staining of tumor tissues. Scale bar equals 70 μm. D, H&E staining of major organs (heart, liver, spleen, lung, and kidney) collected at the endpoint of the in vivo study. Scale bar equals 70 μm.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
In vivo anti-TNBC efficacy of DualADCs in 4T1-Fluc xenograft immunocompetent mouse models. ADCs or saline (16 mg/kg) were i.v. injected via the tail vein. A, Tumor volume measurement with black arrows indicating treatments or saline (n = 4). B, Body weight. C, H&E staining of tumor tissues. Scale bar equals 70 μm. D, H&E staining of major organs (heart, liver, spleen, lung, and kidney) collected at the endpoint of the in vivo study. Scale bar equals 70 μm.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
DAR distribution, average DAR, and DDR of single-payload ADCs and DualADCs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
DAR distribution, average DAR, and DDR of single-payload ADCs and DualADCs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S7 shows bulk RNA-Seq analysis of immune functions in TME.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S7 shows bulk RNA-Seq analysis of immune functions in TME.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S6 shows in vitro cytotoxicity evaluation at low drug concentrations.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S6 shows in vitro cytotoxicity evaluation at low drug concentrations.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S3 shows evaluation of cancer surface binding by DualADCs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S3 shows evaluation of cancer surface binding by DualADCs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer
Supplementary materials and methods, supplementary tables, and supplementary figures
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer
Supplementary materials and methods, supplementary tables, and supplementary figures
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S4 shows MS spectra of intact mAb and fully reduced mAb.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S4 shows MS spectra of intact mAb and fully reduced mAb.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S5 shows Ultra Performance Liquid Chromatography (UPLC) chromatogram used to identify peaks prior to subsequent MS analysis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Advanced CD276-Targeting Dual-Payload Antibody–Drug Conjugates for Cancer Therapy
Figure S5 shows Ultra Performance Liquid Chromatography (UPLC) chromatogram used to identify peaks prior to subsequent MS analysis.